Attention is increasingly being drawn to incentives that are altering medical decisions, driving up costs and channeling men into prostate treatment that delivers negligible benefits when compared to less-expensive care, according to three studies in the past two years and seven doctors who’ve studied prostate treatment. Anthony Zietman, the Jenot W. and William U. Shipley Professor of Radiation Oncology, is quoted.
